HER2 positive endometrial cancer

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
6 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Platinum compound 2 substances
Taxane 2 substances
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Daiichi Sankyo Inc. Commercial
    CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; TRASTUZUMAB DERUXTECAN
    2024-519444-33-00 7 countries 2026 n=200
    Recruiting

Phase II

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Daiichi Sankyo Inc. Commercial 1 Phase III 1
Unicancer Academic 1 Phase II 1
New trials by year
2025
1
2026
1
← All indication landscapes